FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2887709599> ?p ?o ?g. }

• W2887709599 endingPage "84" @default.
• W2887709599 startingPage "1" @default.
• W2887709599 abstract "Background Nicotine preloading means using nicotine replacement therapy prior to a quit date while smoking normally. The aim is to reduce the drive to smoke, thereby reducing cravings for smoking after quit day, which are the main cause of early relapse. A prior systematic review showed inconclusive and heterogeneous evidence that preloading was effective and little evidence of the mechanism of action, with no cost-effectiveness data. Objectives To assess (1) the effectiveness, safety and tolerability of nicotine preloading in a routine NHS setting relative to usual care, (2) the mechanisms of the action of preloading and (3) the cost-effectiveness of preloading. Design Open-label randomised controlled trial with examination of mediation and a cost-effectiveness analysis. Setting NHS smoking cessation clinics. Participants People seeking help to stop smoking. Interventions Nicotine preloading comprised wearing a 21 mg/24 hour nicotine patch for 4 weeks prior to quit date. In addition, minimal behavioural support was provided to explain the intervention rationale and to support adherence. In the comparator group, participants received equivalent behavioural support. Randomisation was stratified by centre and concealed from investigators. Main outcome measures The primary outcome was 6-month prolonged abstinence assessed using the Russell Standard. The secondary outcomes were 4-week and 12-month abstinence. Adverse events (AEs) were assessed from baseline to 1 week after quit day. In a planned analysis, we adjusted for the use of varenicline (Champix ® ; Pfizer Inc., New York, NY, USA) as post-cessation medication. Cost-effectiveness analysis took a health-service perspective. The within-trial analysis assessed health-service costs during the 13 months of trial enrolment relative to the previous 6 months comparing trial arms. The base case was based on multiple imputation for missing cost data. We modelled long-term health outcomes of smoking-related diseases using the European-study on Quantifying Utility of Investment in Protection from Tobacco (EQUIPT) model. Results In total, 1792 people were eligible and were enrolled in the study, with 893 randomised to the control group and 899 randomised to the intervention group. In the intervention group, 49 (5.5%) people discontinued preloading prematurely and most others used it daily. The primary outcome, biochemically validated 6-month abstinence, was achieved by 157 (17.5%) people in the intervention group and 129 (14.4%) people in the control group, a difference of 3.02 percentage points [95% confidence interval (CI) –0.37 to 6.41 percentage points; odds ratio (OR) 1.25, 95% CI 0.97 to 1.62; p = 0.081]. Adjusted for use of post-quit day varenicline, the OR was 1.34 (95% CI 1.03 to 1.73; p = 0.028). Secondary abstinence outcomes were similar. The OR for the occurrence of serious AEs was 1.12 (95% CI 0.42 to 3.03). Moderate-severity nausea occurred in an additional 4% of the preloading group compared with the control group. There was evidence that reduced urges to smoke and reduced smoke inhalation mediated the effect of preloading on abstinence. The incremental cost-effectiveness ratio at the 6-month follow-up for preloading relative to control was £710 (95% CI –£13,674 to £23,205), but preloading was dominant at 12 months and in the long term, with an 80% probability that it is cost saving. Limitations The open-label design could partially account for the mediation results. Outcome assessment could not be blinded but was biochemically verified. Conclusions Use of nicotine-patch preloading for 4 weeks prior to attempting to stop smoking can increase the proportion of people who stop successfully, but its benefit is undermined because it reduces the use of varenicline after preloading. If this latter effect could be overcome, then nicotine preloading appears to improve health and reduce health-service costs in the long term. Future work should determine how to ensure that people using nicotine preloading opt to use varenicline as cessation medication. Trial registration Current Controlled Trials ISRCTN33031001. Funding This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 22, No. 41. See the NIHR Journals Library website for further project information." @default.
• W2887709599 created "2018-08-22" @default.
• W2887709599 creator A5000998614 @default.
• W2887709599 creator A5003374743 @default.
• W2887709599 creator A5005446898 @default.
• W2887709599 creator A5006024585 @default.
• W2887709599 creator A5006328603 @default.
• W2887709599 creator A5006758334 @default.
• W2887709599 creator A5009118198 @default.
• W2887709599 creator A5013599374 @default.
• W2887709599 creator A5015447638 @default.
• W2887709599 creator A5017564785 @default.
• W2887709599 creator A5018562873 @default.
• W2887709599 creator A5018712490 @default.
• W2887709599 creator A5020780991 @default.
• W2887709599 creator A5026669792 @default.
• W2887709599 creator A5026872688 @default.
• W2887709599 creator A5028115760 @default.
• W2887709599 creator A5028874004 @default.
• W2887709599 creator A5028974551 @default.
• W2887709599 creator A5032201852 @default.
• W2887709599 creator A5032326795 @default.
• W2887709599 creator A5033137165 @default.
• W2887709599 creator A5034689040 @default.
• W2887709599 creator A5038542617 @default.
• W2887709599 creator A5038760096 @default.
• W2887709599 creator A5040253323 @default.
• W2887709599 creator A5040725244 @default.
• W2887709599 creator A5047920650 @default.
• W2887709599 creator A5052035076 @default.
• W2887709599 creator A5053836979 @default.
• W2887709599 creator A5060410563 @default.
• W2887709599 creator A5062078849 @default.
• W2887709599 creator A5063609461 @default.
• W2887709599 creator A5064153724 @default.
• W2887709599 creator A5066996772 @default.
• W2887709599 creator A5067667267 @default.
• W2887709599 creator A5071018887 @default.
• W2887709599 creator A5074985418 @default.
• W2887709599 creator A5077716732 @default.
• W2887709599 creator A5077970304 @default.
• W2887709599 creator A5079262492 @default.
• W2887709599 creator A5086731365 @default.
• W2887709599 date "2018-08-01" @default.
• W2887709599 modified "2023-09-27" @default.
• W2887709599 title "Nicotine preloading for smoking cessation: the Preloading RCT" @default.
• W2887709599 cites W128664577 @default.
• W2887709599 cites W1491546893 @default.
• W2887709599 cites W1562781150 @default.
• W2887709599 cites W1564914258 @default.
• W2887709599 cites W1647185577 @default.
• W2887709599 cites W1859891561 @default.
• W2887709599 cites W1931781407 @default.
• W2887709599 cites W1956260915 @default.
• W2887709599 cites W1964649651 @default.
• W2887709599 cites W1971596397 @default.
• W2887709599 cites W1971644218 @default.
• W2887709599 cites W1973007693 @default.
• W2887709599 cites W1973872794 @default.
• W2887709599 cites W1978749922 @default.
• W2887709599 cites W2003078192 @default.
• W2887709599 cites W2004114828 @default.
• W2887709599 cites W2013436152 @default.
• W2887709599 cites W2015072861 @default.
• W2887709599 cites W2017682074 @default.
• W2887709599 cites W2024492508 @default.
• W2887709599 cites W2034175536 @default.
• W2887709599 cites W2036674881 @default.
• W2887709599 cites W2044625851 @default.
• W2887709599 cites W2045213593 @default.
• W2887709599 cites W2054388960 @default.
• W2887709599 cites W2056274890 @default.
• W2887709599 cites W2061382057 @default.
• W2887709599 cites W2067760311 @default.
• W2887709599 cites W2071696300 @default.
• W2887709599 cites W2074854406 @default.
• W2887709599 cites W2077332137 @default.
• W2887709599 cites W2080546487 @default.
• W2887709599 cites W2084289344 @default.
• W2887709599 cites W2094697878 @default.
• W2887709599 cites W2095328553 @default.
• W2887709599 cites W2101814434 @default.
• W2887709599 cites W2106203584 @default.
• W2887709599 cites W2113500805 @default.
• W2887709599 cites W2114894395 @default.
• W2887709599 cites W2118061336 @default.
• W2887709599 cites W2119616168 @default.
• W2887709599 cites W2122640943 @default.
• W2887709599 cites W2123974278 @default.
• W2887709599 cites W2127817571 @default.
• W2887709599 cites W2129820723 @default.
• W2887709599 cites W2134843796 @default.
• W2887709599 cites W2138106394 @default.
• W2887709599 cites W2149818961 @default.
• W2887709599 cites W2159030880 @default.
• W2887709599 cites W2167994577 @default.
• W2887709599 cites W2168309269 @default.
• W2887709599 cites W2170477339 @default.

• next